Utilization of Formulation and Devices for Intranasal Delivery

• Highlight general formulation and delivery learnings from model peptide/biologic compounds and how they pair with Aptar devices and proof of concept in vivo data
• Discuss formulation and device strategies to enable delivery of mucosal vaccines
• Emphasize using formulation, device, and in vivo studies to address problem statements in intranasal drug delivery with the following

Speakers:

Philip Kuehl

Director of Science and Technology

Aptar Group Inc